Lite Strategy (LITS) Research & Development (2010 - 2026)
Lite Strategy (LITS) posted quarterly Research & Development of $30000.0 for Q1 2026, down 91.87% year-over-year from $369000.0 in Q1 2025, and down 34.78% quarter-over-quarter from $46000.0 in Q4 2025.
Lite Strategy (LITS) Research & Development (2010 - 2026) Analysis & Trends
Lite Strategy's Research & Development history runs 17 years deep, the most recent figure standing at $30000.0 for Q1 2026.
- In Q1 2026, Research & Development fell 91.87% year-over-year to $30000.0; the TTM figure through Mar 2026 stood at $169000.0 (down 97.83% YoY), while the FY2025 annual figure was $3.9 million, down 76.31% from the prior year.
- Research & Development for Q1 2026 stood at $30000.0, down from $46000.0 in the prior quarter.
- The five-year high for Research & Development was $22.3 million in Q1 2022, with the low at $10000.0 in Q3 2025.
- The 5-year median for Research & Development is $3.5 million (2023), against an average of $6.9 million.
- The sharpest annual moves came in 2024 and 2025: Research & Development surged 53.46% in 2024, then slumped 99.68% in 2025.
- Lite Strategy's Research & Development stood at $15.3 million in 2022, then tumbled by 74.45% to $3.9 million in 2023, then tumbled by 92.13% to $308000.0 in 2024, then slumped by 85.06% to $46000.0 in 2025, then plunged by 34.78% to $30000.0 in 2026.
- Business Quant data shows LITS's Research & Development at $30000.0 in Q1 2026, $46000.0 in Q4 2025, and $10000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Lite Strategy | 33.69 Mn | 26.14 Mn | - | 30,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 30,000.00 |
| Dec 31, 2025 | 46,000.00 |
| Sep 30, 2025 | 10,000.00 |
| Jun 30, 2025 | 83,000.00 |
| Mar 31, 2025 | 369,000.00 |
| Dec 31, 2024 | 308,000.00 |
| Sep 30, 2024 | 3.16 Mn |
| Jun 30, 2024 | 3.94 Mn |
| Mar 31, 2024 | 5.22 Mn |
| Dec 31, 2023 | 3.91 Mn |
| Sep 30, 2023 | 3.49 Mn |
| Jun 30, 2023 | 2.57 Mn |
| Mar 31, 2023 | 15.10 Mn |
| Dec 31, 2022 | 15.31 Mn |
| Sep 30, 2022 | 19.46 Mn |
| Jun 30, 2022 | 21.84 Mn |
| Mar 31, 2022 | 22.32 Mn |
| Dec 31, 2021 | 21.53 Mn |
| Sep 30, 2021 | 19.95 Mn |
| Jun 30, 2021 | 16.29 Mn |